AzTrials
AzTrials

Recurrent Transformed Chronic Lymphocytic LeukemiaPhase 2NCT06247540

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2 study testing Biopsy, Biospecimen Collection and Bone Marrow Biopsy in people with Recurrent Transformed Chronic Lymphocytic Leukemia and Refractory Transformed Chronic Lymphocytic Leukemia, run by Northwestern University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Biopsy, Biospecimen Collection and Bone Marrow Biopsy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
29 Mar 2024to 29 Dec 2031
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must have a confirmed diagnosis of one of Richter's transformation (to either diffuse large B cell lymphoma (DLBCL) or Hodgkin's lymphoma) with preceding CLL/SLL
  • Richter's transformation refers to development of aggressive lymphoma (most commonly diffuse large B cell lymphoma (DLBCL), and less commonly Hodgkin's lymphoma) in a patient who has a pre-existing diagnosis of CLL/SLL. A pathologic diagnosis of DLBCL or Hodgkin's lymphoma in the setting of preceding CLL/SLL is required
  • Patients with Richter's transformation arising from CLL/SLL may be newly diagnosed or have relapsed or progressed after prior treatment. Patients with newly diagnosed Richter transformation are eligible only if the treating physician believes they are not good candidates for standard immunochemotherapy or chemotherapy
  • All patients must have measurable disease as defined by Lugano criteria 2014
  • Patients must be age ≥ 18 years
  • Patients must exhibit a/an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Show all 27Show fewer
  • Absolute neutrophil count ≥ 1,000/mcL (independent of growth factor support for ≥ 14 days) (within 14 days prior to registration)
  • Platelets ≥ 30,000/mcl (independent of transfusion for ≥ 14 days) (within 14 days prior to registration)
  • Hemoglobin ≥ 8 g/dL (within 14 days prior to registration)
  • Note: patients must be able to maintain this level without transfusion
  • Total bilirubin < 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to registration)
  • Note: Autoimmune hemolytic anemia (AIHA) and Gilbert's syndrome are exceptions and bilirubin value must be < 5 x ULN
  • Aspartate aminotransferase (AST) ( serum glutamic-oxaloacetic transaminase [SGOT]) ≤ 1.5 X ULN (within 14 days prior to registration)
  • Alanine transaminase (ALT) (serum glutamic-pyruvic transaminase [SPGT]) ≤ 1.5 X ULN (within 14 days prior to registration)
  • Creatinine clearance ≥ 50mL/min (within 14 days prior to registration)
  • Calculate creatinine clearance (CrCl) using the Cockcroft Gault
  • Patients with a known history chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a known history of hepatitis C (HCV) infection must have been treated and cure. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Females of child-bearing potential (FOCBP) must agree to adequate contraception (abstinence or acceptable methods of birth control such as barrier method or hormonal contraception) with partner(s) for the duration of study participation, for 5 months after the last dose of nivolumab and 12 months after the last dose of rituximab following completion of therapy.
  • NOTE: A FOCBP is any woman (regardless of sexual orientation, including women who having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  • Has not undergone a hysterectomy or bilateral oophorectomy
  • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months; confirmation of postmenopausal state will be done by clinical history of last menstrual period)
  • FOCBP must have a negative urine or serum pregnancy test within 7 days prior to registration on study.
  • NOTE: Patients are also required to have a negative pregnancy test within 24 hours of first dose of study drug
  • Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
  • Patients must have the ability to swallow and maintain oral medication
  • Patients must be willing and able to start treatment with allopurinol or equivalent ≤ 3 days prior to starting treatment with venetoclax

Who cannot join

  • Patients who have received prior nivolumab for treatment of Richter's transformation, or other PD-1/PD-L1 for the treatment of any indication.
  • Note: Prior anti-CD-20 antibody treatment is allowed with ≥ 14 day washout period. Prior treatment with nivolumab is permissible if for a different disease indication. In such cases nivolumab must have been discontinued ≥ 3 months prior to registration
  • Patients who have a history of life-threatening adverse reactions attributed to compounds of similar chemical or biologic composition to venetoclax, nivolumab, or rituximab
  • Patients who are refractory to venetoclax (defined by disease progression while on venetoclax or within 3 months of discontinuing venetoclax)
  • Patients who have had prior chimeric antigen receptor-modified T-cell (CAR-T) therapy within the 45 days prior to registration or with any remaining CAR-T related cytokine-release syndrome or neurotoxicity
  • Patients who have adverse events due to agents administered ≥ 30 days prior to registration that have not recovered to ≤ grade 2
Show all 34Show fewer
  • Patients who have had chemotherapy, radiotherapy or immunotherapy ≤ 14 days prior to registration
  • Patients receiving any other investigational agents within ≤ 30 days or 5 half-lives prior to registration, whichever is shorter
  • Patients who have received B-cell receptor pathway inhibitor (such as ibrutinib or idelalisib) ≤ 3 days prior to receiving study treatment
  • Patients who have undergone an autologous stem cell transplant ≤ 120 days prior to registration
  • Patients who have undergone an allogeneic stem cell transplant ≤ 180 days prior to registration.
  • Note: Patients must be off all immunosuppressive therapies > 30 days prior to registration, with no active graft versus host disease (GVHD)
  • Patients with acute or extensive chronic graft-versus-host disease (GVHD)
  • Patients who have received any of the following agents ≤ 7 days prior to receiving study treatment:
  • Steroid therapy with anti-neoplastic intent
  • Moderate or strong CYP3A inhibitors
  • Moderate or strong CYP3A inducers
  • Patients who have received a live / attenuated vaccine ≤ 30 days prior to receiving study treatment
  • Patients who have history of auto-immune conditions requiring ongoing or intermittent systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive medications)
  • Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Patients who have a history of active malignancy other than CLL/SLL or RT within the past 2 years, with the exception of:
  • Adequately treated in situ carcinoma of the cervix uteri
  • Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
  • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
  • Patients who have known autoimmune disease or active uncontrolled autoimmune cytopenias
  • Patients who have overt thyroid dysfunction (hyperthyroidism or hypothyroidism).
  • Note: Patients with chronic hypothyroidism taking stable dose of thyroid replacement therapy with normal TSH are eligible
  • Patients with systemic fungal, bacterial, viral, or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment
  • Any patient who has tested positive for human immunodeficiency virus (HIV) (due to potential drug-drug interactions between anti-retroviral medications and venetoclax, as well as anticipated venetoclax mechanism based lymphopenia that may potentially increase the risk of opportunistic infections).
  • Note: HIV test is not a requirement to determine eligibility
  • Patients who have malabsorption syndrome or another condition that precludes enteral route of administration
  • Patients with a known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase
  • Patients who have a significant history of cardiovascular, pulmonary, renal, hepatic, neurologic, psychiatric, endocrinologic, metabolic, or immunologic disease that in the opinion of the investigator would adversely affect his/her participation in this study or interpretation of study results
  • Patients who are pregnant or nursing

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Northwestern University

    Chicago, Illinois, 60611

Other trials in United States

About this study

Official title: Venetoclax, Rituximab and Nivolumab Combination in Patients With Richter's Transformation (RT) Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Phase II Study With Safety Run-In

This phase II trial tests how well venetoclax, rituximab and nivolumab works in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Richter's transformation. Richter's transformation can be described as the development of an aggressive lymphoma in the setting of underlying CLL/SLL that has a very poor prognosis with conventional therapies and represents a significant unmet medical need. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as rituximab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving venetoclax, rituximab and nivolumab together may work better than the conventional intensive immunochemotherapy to improve disease control in patients with Richter's transformation arising from CLL/SLL.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To determine the preliminary efficacy in terms of overall response rate (ORR) per Lugano criteria with venetoclax, nivolumab, and rituximab combination in patients with Richter's transformation.

SECONDARY OBJECTIVES:

  1. To determine the safety and tolerability of venetoclax, nivolumab, and rituximab combination in Richter's transformation (RT) using Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).

II. To determine preliminary efficacy in terms of complete response (CR) with venetoclax, nivolumab, and rituximab combination in patients with RT.

III. To determine the preliminary efficacy in terms of minimal residual disease (MRD) negativity rate with venetoclax, nivolumab, and rituximab combination in patients with RT.

IV. To determine the preliminary efficacy in terms of progression free survival (PFS) at 12 months with venetoclax, nivolumab, and rituximab combination in patients with RT.

  1. To determine the preliminary efficacy in terms of overall survival (OS) with venetoclax, nivolumab, and rituximab combination in patients with RT.

EXPLORATORY OBJECTIVES:

  1. The study team will study various prognostic markers and biomarkers and correlate them with clinical response:

Ia. MRD status in bone marrow and peripheral blood; Ib. CLL prognostic markers, cytogenetics abnormalities by fluorescence in situ hybridization (FISH), IgVH mutation status, and TP53 mutation status; Ic. PD-L1 and PD-1 expression by immunohistochemistry (IHC), either in lymph node tissue samples or bone marrow; Id. T-cell subsets in the blood and tissue biopsy.

EXPLORATORY STUDIES OBJECTIVES:

  1. To determine the clinical and pathological factors impacting clinical response to the rituximab-nivolumab-venetoclax combination therapy.

II. To study the role of PD-1 blockade in RT. III. To determine the role of bone marrow and peripheral blood MRD in the RT study population.

OUTLINE: This is a dose-escalation study of venetoclax.

Patients receive venetoclax orally (PO) once daily (QD) on days 1-28, nivolumab intravenously (IV) over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as positron emission tomography (PET)/computed tomography (CT) and CT or magnetic resonance imaging (MRI) during screening and on the trial.

After completion of study treatment, patients are followed up at 30 days and every 90 days for 5 years from the start of treatment.

Being tested
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BiopsyProcedure or surgery

    Also called BIOPSY_TYPE, Bx

    Undergo tissue biopsy

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood sample collection

  • Bone Marrow BiopsyProcedure or surgery

    Also called Biopsy of Bone Marrow, Biopsy, Bone Marrow

    Undergo bone marrow biopsy

  • Computed TomographyProcedure or surgery

    Also called CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography

    Undergo PET/CT, CT

  • Magnetic Resonance ImagingProcedure or surgery

    Also called Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance

    Undergo MRI

  • NivolumabBiological

    Also called ABP 206, BMS-936558, CMAB819, MDX-1106

    Receive IV

  • Positron Emission TomographyProcedure or surgery

    Also called Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure)

    Undergo PET/CT

  • RituximabBiological

    Also called ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody

    Receive IV

  • VenetoclaxDrug

    Also called ABT-0199, ABT-199, ABT199, GDC-0199

    Receive PO

Study groups in NCT06247540
Study groupRoleWhat they receive
Treatment (venetoclax, rituximab, nivolumab)ExperimentalPatients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.
Receives: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Procedure: Positron Emission Tomography; Biological: Rituximab; Drug: Venetoclax

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall response rate

    Will be assessed using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) and Lugano 2014 criteria for Richter's transformation (RT) patients. Will be calculated using proportions and exact 95% binomial confidence intervals.

    Measured: Up to 5 years

  2. Best response rate

    Will be assessed using iwCLL and Lugano 2014 criteria for RT patients. Will be calculated using proportions and exact 95% binomial confidence intervals.

    Measured: Up to 5 years

  3. Minimal residual disease (MRD) rate

    Will be assessed in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients in the peripheral blood and bone marrow by flow cytometry, polymerase chain reaction (PCR) and/or sequencing. MRD negativity is defined as less than one CLL/SLL cell per 10,000 leukocytes (or below 10-4) on peripheral blood and/or bone marrow based flow cytometry and/or PCR based methods. Rate of MRD status will be defined as the proportion of patients who have MRD negativity status. Will be calculated using proportions and exact 95% binomial confidence intervals.

    Measured: Up to 5 years

Secondary outcomes (5)

  1. Incidence of adverse events

    Will calculate the number and percentage of toxicities by type, grade, severity and attribution. For all adverse events including laboratory values, physical examination characteristics, vital signs and electrocardiogram, Common Terminology Criteria for Adverse Events version 5.0 criteria will be used to classify the severity of the adverse event. All adverse events regardless of severity will be documented and will be summarized for regular review by the Cancer Center's Data and Safety Monitoring Committee.

    Measured: Up to 100 days after last dose of study treatment

  2. Progression-free survival

    Will be assessed using iwCLL and Lugano 2014 criteria for RT patients. Will be determined using a Kaplan-Meier curves with 5-year survival and 95% confidence interval reported

    Measured: Up to 5 years

  3. Overall survival

    Will be determined using a Kaplan-Meier curves with 5-year survival and 95% confidence interval reported

    Measured: Up to 5 years

  4. Duration of response

    Will be assessed using iwCLL and Lugano 2014 criteria for RT patients. Will be summarized using median and interquartile range.

    Measured: Up to 5 years

  5. Prognostic markers and biomarkers

    Will be correlated with clinical response using a Wilcoxon rank sum test. The statistical significance of individual markers, multivariate proportional hazards regression will be used to assess multiple markers simultaneously. Prognostic markers will be related to response using Fisher's exact test or the Wilcoxon rank sum test.

    Measured: Up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2024
  2. Study start29 Mar 2024 (estimated)
  3. Primary completion29 Dec 2029 (estimated)
  4. Study completion29 Dec 2031 (estimated)

Why it stopped: Funding

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06247540
Sponsor's protocol ID
NU 23H01
Other IDs
NCI-2023-08755, STU00219856, NU 23H01, P30CA060553
Status last verified
Feb 2024
First submitted
8 Dec 2023
Last updated
29 Feb 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Biopsy, Biospecimen Collection and Bone Marrow Biopsy in people with Recurrent Transformed Chronic Lymphocytic Leukemia and Refractory Transformed Chronic Lymphocytic Leukemia, run by Northwestern University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 29 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall response rate (time frame: Up to 5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06247540.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Feb 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in